All In Biotech

Drug Trial Radar · NCT01967225

Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections

A Prospective, Randomized, Open-label, Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of BAY 1192631 in Japanese Patients With MRSA Infections (Skin and Soft Tissue Infection [SSTI] and SSTI-related Bacteremia)

Last checked: Nov 20, 2026Latest source record: Oct 4, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 125 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

125

Actual

Start

Nov 23, 2013

Primary completion

Oct 28, 2016

Study completion Oct 28, 2016

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Oct 22, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to see the efficacy and safety of BAY1192631 in Japanese patients with methicillin-resistant staphylococcus aureus (MRSA) (skin and soft tissue infections (SSTI) and SSTI-related bacteremia).

Conditions

  • Skin Diseases, Infectious

Interventions

  • Tedizolid Phosphate (Sivextro, BAY1192631)Drug

    BAY1192631 solution or tablet 200 mg, once daily, Intravenous (IV) or By Mouth (PO) for 7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia.

  • LinezolidDrug

    Linezolid solution or tablet 600 mg, twice daily, every 12 ±3 hours, Intravenous (IV) or By mouth (PO) 7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Response at Test of Cure (TOC)Time frame: 7-14 days after the end of treatment (EOT) for skin and soft tissue infections (SSTI) and 4-6 weeks after EOT for bacteremia
  2. Microbiological Response at Test of Cure (TOC)Time frame: 7-14 days after the end of treatment (EOT) for skin and soft tissue infections (SSTI) and 4-6 weeks after EOT for bacteremia

Locations

46 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Fukuoka, Japan

  • Site not named

    Gifu, Japan

  • Site not named

    Kochi, Japan

  • Site not named

    Kumamoto, Japan

  • Site not named

    Nagasaki, Japan

  • Site not named

    Osaka, Japan

  • Site not named

    Shizuoka, Japan

  • Site not named

    Shizuoka, Japan

  • Site not named

    Toyama, Japan

  • Site not named

    Nagakute, Aichi-ken, Japan

  • Site not named

    Nagoya, Aichi-ken, Japan

  • Site not named

    Nagoya, Aichi-ken, Japan

  • Site not named

    Toyoake, Aichi-ken, Japan

  • Site not named

    Yoshida, Fukui, Japan

  • Site not named

    Kasuga, Fukuoka, Japan

  • Site not named

    Kitakyushu, Fukuoka, Japan

  • Site not named

    Miyako-gun, Fukuoka, Japan

  • Site not named

    Sapporo, Hokkaido, Japan

  • Site not named

    Sapporo, Hokkaido, Japan

  • Site not named

    Amagasaki, Hyōgo, Japan

  • Site not named

    Kobe, Hyōgo, Japan

  • Site not named

    Inashiki-gun, Ibaraki, Japan

  • Site not named

    Tsukuba, Ibaraki, Japan

  • Site not named

    Kamakura, Kanagawa, Japan

  • Site not named

    Sagamihara, Kanagawa, Japan

  • Site not named

    Yokohama, Kanagawa, Japan

  • Site not named

    Kōshi, Kumamoto, Japan

  • Site not named

    Tsu, Mie-ken, Japan

  • Site not named

    Sendai, Miyagi, Japan

  • Site not named

    Nakagami-gun, Okinawa, Japan

  • Site not named

    Shimajiri, Okinawa, Japan

  • Site not named

    Hamamatsu, Shizuoka, Japan

  • Site not named

    Iwata, Shizuoka, Japan

  • Site not named

    Numazu, Shizuoka, Japan

  • Site not named

    Meguro-ku, Tokyo, Japan

  • Site not named

    Musashimurayama, Tokyo, Japan

  • Site not named

    Ōta-ku, Tokyo, Japan

  • Site not named

    Ōta-ku, Tokyo, Japan

  • Site not named

    Ōta-ku, Tokyo, Japan

  • Site not named

    Setagaya-ku, Tokyo, Japan

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.